These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30066999)

  • 1. Delayed hypersensitivity to new oral anticoagulants. Demonstration of cross reactivity for the drug category and definition of non-irritant concentrations for patch tests.
    Cortellini G; Rossi F; Lippolis D; Cortellini F; Gavioli B; Ballardini G
    Eur Ann Allergy Clin Immunol; 2019 Jan; 51(1):38-40. PubMed ID: 30066999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed hypersensitivity reactions to edoxaban.
    Franceschini L; Carli G; Landini G; Matarrese D; Farsi A
    Ann Allergy Asthma Immunol; 2021 Jan; 126(1):95-96. PubMed ID: 32866622
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypersensitivity reactions to non-vitamin K oral anticoagulants - a review of literature and diagnostic work-up proposal.
    Carli G; Farsi A; Chiarini F; Lippolis D; Cortellini G
    Eur Ann Allergy Clin Immunol; 2019 Jan; 51(1):7-14. PubMed ID: 30417637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy and safety of edoxaban in non-valvular atrial fibrillation].
    Szegedi A; Csanádi Z
    Orv Hetil; 2018 Mar; 159(12):466-469. PubMed ID: 29552925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
    Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
    Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
    Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin.
    Yamaji H; Murakami T; Hina K; Higashiya S; Kawamura H; Murakami M; Kamikawa S; Hirohata S; Kusachi S
    J Cardiovasc Electrophysiol; 2018 Jun; 29(6):835-843. PubMed ID: 29533476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stroke prevention in the elderly: effectiveness and safety of edoxaban in elderly patients according to the results of the ENGAGE AF study].
    Márk L
    Orv Hetil; 2018 May; 159(20):798-802. PubMed ID: 29754512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Minguet J; Sims HM; Smith KH; Bramlage P
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Chen J; Zhuang X; Long M; Su C; Wang L
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2710-9. PubMed ID: 26324517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
    Bohula EA; Giugliano RP; Ruff CT; Kuder JF; Murphy SA; Antman EM; Braunwald E
    Circulation; 2016 Jul; 134(1):24-36. PubMed ID: 27358434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
    Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
    Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation.
    Vu TT; Gooderham M
    J Cutan Med Surg; 2017; 21(6):540-550. PubMed ID: 28639463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
    Mendell J; Lee F; Chen S; Worland V; Shi M; Samama MM
    J Cardiovasc Pharmacol; 2013 Aug; 62(2):212-21. PubMed ID: 23615159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eczema-like plaques to enoxaparin.
    Valdés F; Vidal C; Fernández-Redondo V; Peteiro C; Toribio J
    Allergy; 1998 Jun; 53(6):625-6. PubMed ID: 9689351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.